Pritelivir, an investigational antiviral for herpes simplex virus, demonstrated strong efficacy in a phase 3 trial, with 62.7 ...

Pritelivir, an investigational antiviral drug for herpes simplex virus, demonstrated “superior efficacy” in healing lesions ...

In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete ...

Herpes simplex virus type 1 (HSV-1) infection dramatically remodels the host cell's nuclear structures. Infection leads to the formation of viral replication compartments and to chromatin ...

A modified herpes virus boosted immune T cell infiltration in glioblastoma tumors and was associated with improved survival.

– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...

New research using US insurance data finds that people with HSV-1 face greater odds of Alzheimer’s disease, and suggests antiviral medications could help lower that risk. Study: Association between ...

Inhibiting the herpes simplex virus type 1 viral enzyme uracil-DNA glycosylase reactivates the natural defense protein apolipoprotein B mRNA editing enzyme, catalytic polypeptide-1 (APOBEC1) in the ...

Researchers found that Herpes simplex virus type 1 reorganizes nuclear speckles, essential sites for RNA processing. Without ...